Fortress Biotech Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 18.5% | 30.2% | 46.1% | 43.9% | 36.1% | 38.4% | 36.5% | 30.1% | 32.6% | 33.8% | 45.8% | 38.0% | 37.5% | |
| 81.5% | 69.8% | 53.9% | 56.1% | 63.9% | 61.6% | 63.5% | 69.9% | 67.4% | 66.2% | 54.2% | 62.0% | 62.5% | |
| 58.6% | 70.6% | 190.6% | 85.1% | 64.6% | 65.7% | 30.0% | 49.5% | 1.2% | 2.3% | 3.4% | 4.3% | 2.8% | |
| 62.5% | 113.4% | 137.7% | 139.8% | 150.3% | 177.7% | 195.3% | 236.1% | 98.8% | 91.6% | 99.1% | 111.2% | 100.6% | |
| 121.1% | 168.2% | 334.6% | 242.6% | 214.9% | 242.5% | 233.4% | 292.1% | 106.0% | 96.0% | 102.5% | 115.5% | 105.4% | |
| -39.6% | -98.3% | -280.6% | -186.5% | -151.0% | -180.9% | -169.9% | -222.2% | -38.6% | -29.8% | -48.3% | -53.5% | -42.9% | |
| 7.3% | 10.3% | 20.0% | 14.2% | 42.4% | 17.2% | 19.1% | 12.6% | 13.7% | 10.6% | 21.0% | 7.9% | 13.1% | |
| -30.5% | -143.4% | -299.5% | -193.5% | -182.0% | -171.8% | -187.9% | -71.0% | 50.2% | -38.6% | 887.2% | 4.8% | 213.0% | |
| 0.4% | 1.9% | -13.2% | -17.2% | 0.5% | 2.2% | – | – | 0.1% | -5.1% | 32.0% | 1.6% | 6.8% | |
| -14.5% | -46.5% | -118.3% | -73.5% | -88.0% | -44.7% | -80.6% | 94.4% | 33.2% | -24.5% | 688.2% | -2.5% | 163.3% | |
| -17.1% | -127.2% | -275.0% | -175.5% | -144.0% | -144.0% | -159.8% | -51.3% | 70.5% | -20.8% | 918.8% | 17.9% | 233.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.